Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?
Pharmaceutical Technology
JUNE 6, 2023
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Buy the model here.
Let's personalize your content